A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)
Phase 3
Completed
NCT04969224
| Condition | Cystic Fibrosis |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Vertex Pharmaceuticals Incorporated |
|---|
| Status | Completed |
|---|
| Enrollment | 82 participants |
|---|
| Interventions | ELX/TEZ/IVA, IVA |
|---|
| Start date | Oct 12, 2021 |
|---|
| Completion date | Jul 26, 2022 |
|---|
| Results posted | Oct 3, 2023 |
|---|
Summary
This study will evaluate the effects of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on cough and physical activity using wearable technology in CF participants.
Percent Reduction From Baseline in Cough Frequency (Cough Events Per Day) to the Average of Week 8 Through Week 12
Baseline, Week 8 through Week 12 · percent reduction
| ELX/TEZ/IVA | 91.7 percent reduction |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.